Effects of disease modifying therapies on brain and grey matter atrophy in relapsing remitting multiple sclerosis

Overview of attention for article published in Multiple Sclerosis and Demyelinating Disorders, January 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (81st percentile)

Mentioned by

policy: 1 policy source
twitter: 4 X users

wikipedia: 2 Wikipedia pages

Citations

dimensions_citation: 22 Dimensions

Readers on

mendeley: 21 Mendeley

Summary Policy documents X Wikipedia Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

Ozanimod for treating relapsing–remitting multiple sclerosis : Appraisal consultation committee papers

Cited by National Institute for Health and Care Excellence on 22 Jan 2021

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.